Respiratory Viral Infection Clinical Trials

10 recruitingLast updated: July 25, 2026

There are 10 actively recruiting respiratory viral infection clinical trials across 8 countries. Studies span Phase 3, Phase 1, Phase 2, Not Applicable. Top locations include Saint Petersburg, Russia, Perm, Russia, Ann Arbor, Michigan, United States. Updated daily from ClinicalTrials.gov.


Respiratory Viral Infection Trials at a Glance

10 actively recruiting trials for respiratory viral infection are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 3 with 3 trials, with the heaviest enrollment activity in Saint Petersburg, Perm, and Ann Arbor. Lead sponsors running respiratory viral infection studies include Valenta Pharm JSC, Joincare Pharmaceutical Group Industry Co., Ltd, and Hospices Civils de Lyon.

Browse respiratory viral infection trials by phase

Treatments under study

About Respiratory Viral Infection Clinical Trials

Looking for clinical trials for Respiratory Viral Infection? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Respiratory Viral Infection trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Respiratory Viral Infection clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1

Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.

InfluenzaAcute Respiratory Viral Infections
Valenta Pharm JSC36 enrolled1 locationNCT07645534
Recruiting
Phase 2

A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses

Respiratory Viral Infection
SynAct Pharma Aps96 enrolled11 locationsNCT07633288
Recruiting

Assessment of the Type I IFN Response in the Nasal Cavity During Respiratory Viral Infections in a Geriatric Department

Respiratory Viral Infection
Hospices Civils de Lyon1,140 enrolled1 locationNCT07601412
Recruiting
Phase 1

Macrophage Regulation of Ozone-Induced Lung Inflammation

Respiratory Viral Infection
Robert Tighe, MD100 enrolled1 locationNCT05773001
Recruiting
Phase 3

Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years

Acute Respiratory Viral Infection
Materia Medica Holding374 enrolled35 locationsNCT06715891
Recruiting
Not Applicable

Dime La VerDAD: Verify, Debunk, and Disseminate

COVID-19Health BehaviorInfluenza+2 more
University of Chicago1,400 enrolled4 locationsNCT06417762
Recruiting
Phase 2

Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.

InfluenzaAcute Respiratory Viral Infection
Valenta Pharm JSC300 enrolled11 locationsNCT07420985
Recruiting
Phase 3

Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza

Respiratory Viral Infection
Joincare Pharmaceutical Group Industry Co., Ltd177 enrolled1 locationNCT07357051
Recruiting
Phase 3

Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza

Respiratory Viral Infection
Nanjing Zenshine Pharmaceuticals168 enrolled2 locationsNCT07095257
Recruiting

Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

Solid Organ TransplantHematopoietic Cell TransplantRespiratory Viral Infection
Arkansas Children's Hospital Research Institute2,000 enrolled27 locationsNCT05550298